Solventum to sell purification and filtration business to Thermo Fisher for $4.10 billion
Solventum agreed on February 25, 2025 to sell its purification and filtration business to Thermo Fisher Scientific for approximately $4.10 billion in cash, plus assumption of certain liabilities, subject to customary closing adjustments. The deal is subject to closing conditions, including antitrust clearance, and Solventum expects to close by the end of 2025, so shareholders face a pending divestiture rather than a completed sale.
Key points
- Cash consideration of approximately $4.10 billion payable at closing, subject to adjustments for cash, debt, transaction expenses and working capital
- Agreement dated February 25, 2025; Solventum expects to close by the end of the 2025 calendar year
- Either party may terminate if the deal is not completed by November 25, 2025, with two three-month extensions available if only regulatory conditions remain unmet
- Solventum agreed to a three-year non-compete for the business and a two-year non-solicit and no-hire for certain employees after closing
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.